Citations

Clear

626 citation(s) found for "Mehta, SH".

Causes and Predictors of Readmission in Patients With Atrial Fibrillation Undergoing Catheter Ablation: A National Population‐Based Cohort Study
Arora, Shilpkumar , Lahewala, Sopan , Tripathi, Byomesh , Mehta, Varshil , Kumar, Varun , Chandramohan, Divya , Lemor, Alejandro , Dave, Mihir, Patel, Nileshkumar , Patel, Nilay , Shantha, Ghanshyam Palamaner Subash , Viles-González, Juan F., Deshmukh, Abhishek

Mayo Clinic

Journal of the American Heart Association | June 15, 2018 | Volume: 7 | Issue: 12 | Pages: No page available

10.1161/jaha.118.009294 | PMID 29907655 Get It

Background Reducing readmission after catheter ablation ( CA ) in atrial fibrillation (AF) is important. Methods and Results We utilized National Readmission Data ( NRD ) 2010–2014. AF was identified by International Classification of Diseases, Ninth Edition, Clinical Modification (ICD‐9‐CM) diagnostic code 427.31 in the primary field, while first CA of AF was identified via ICD‐9 ‐procedure code 37.34. Any admission within 30 or 90 days of index admission was considered a readmission. Cox proportional hazard regression was used to adjust for confounders. The primary outcomes were 30‐ and 90‐day readmissions and the secondary outcome was AF recurrence. In total, 1 128 372 patients with AF were identified from January 1, 2010 to September 30, 2014. Of which 37 360 (3.3%) underwent CA . Patients aged ≥65 years and female sex were less likely to receive CA for AF . Overall, 10.9% and 16.5% of CA patients were readmitted within 30 and 90 days post‐CA, respectively. Most common causes of readmissions were arrhythmia ( AF , atrial flutter), heart failure, pulmonary causes (pneumonia, chronic obstructive pulmonary disease) and bleeding complications (gastrointestinal bleed, intracranial hemorrhage). Patients with diabetes mellitus, heart failure, coronary artery disease ( CAD ), chronic pulmonary and kidney disease, prior stroke/transient ischemic attack (TIA), female sex, length of stay ≥2 and disposition to the facility were prone to higher 30‐ and 90‐day readmissions post ‐CA . Predictors of increase in AF recurrence post‐ CA were female sex, diabetes mellitus, chronic pulmonary disease, and length of stay ≥2. Trends of 90‐day readmission and AF recurrence were found to improve over the study period. Conclusions We identified several demographic and clinical factors associated with the use of CA in AF , and short‐term outcomes of the same, which could potentially help in the patient selection and improve outcomes.
Preoperative Vs Postoperative Radiosurgery For Resected Brain Metastases: A Review
Prabhu, Roshan S. , Patel, Kirtesh R., Soltys, Scott G. , Brown, Paul D. , Asher, Anthony L. , Burri, Stuart H., Press, Robert H. , Mehta, Minesh P.

Mayo Clinic

Neurosurgery | March 25, 2018 | Volume: 84 | Issue: 1 | Pages: 19-29

10.1093/neuros/nyy146 | PMID 29771381 Get It

Abstract Patients who undergo surgical resection of brain metastases are at significant risk of cavity local recurrence without additional radiation therapy. Postoperative stereotactic radiosurgery (SRS) is a method of focal treatment to the cavity to maximize local control while minimizing the risk of neurocognitive detriment associated with whole brain radiation therapy. Recently published randomized trials have demonstrated the benefit of postoperative SRS in terms of cavity tumor control and preserving neurocognition. However, there are several potential drawbacks with postoperative SRS including a possible increase in symptomatic radiation necrosis because of the need for cavity margin expansion due to target delineation uncertainty, the variable postoperative clinical course and potential delay in administering postoperative SRS, and the theoretical risk of tumor spillage into cerebrospinal fluid at the time of surgery. Preoperative SRS is an alternative paradigm wherein SRS is delivered prior to surgical resection, which may effectively address some of these potential drawbacks. The goal of this review is to examine the rationale, technique, outcomes, evidence, and future directions for the use of SRS as an adjunct to surgical resection. This can be delivered as either preoperative or postoperative SRS with potential advantages and disadvantages to both approaches that will be discussed.
P1218Incidence and Risk Factors for Renal Dysfunction after Direct Current Cardioversion of Atrial Fibrillation
Grüner‐Hegge, Nicolai, Padmanabhan, Deepak , Mehta, Rajesh , Hodge, D, Meludini, R, Rihal, C., Mulpuru, Siva K. , Deshmukh, Abhishek , Ammash, Naser M., Greene, Eddie L., Friedman, Paul A. , Kella, Danesh , Mehta, R, Hodge, D

Mayo Clinic

EP Europace | March 19, 2018 | Volume: 20 | Issue: suppl_1 | Pages: i239-i239

10.1093/europace/euy015.700 Get It

207Clinical utility of performing magnetic resonance imaging in patients with cardiac implantable electronic devices in situ
Padmanabhan, Deepak , Tandon, Navdeep, Mulpuru, Siva K. , Mehta, Ramila A. , Dalzell, Connie, Olson, Nora E., Felmlee, Joel P. , Jondal, Mary Lou, Watson, Robert E. , Cha, YONG-M, Friedman, Paul A. , Kella, Danesh , Deshmukh, Amrish , Kapa, Suraj , Asirvatham, Samuel J.

Mayo Clinic

EP Europace | March 19, 2018 | Volume: 20 | Issue: suppl_1 | Pages: i22-i23

10.1093/europace/euy015.056 Get It

Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes
Hall, William A. , Pugh, Stephanie L. , Armstrong, Terri S. , Brachman, David, Werner‐Wasik, Maria, Wendland, Merideth M, Brown, Paul D. , Chao, Samuel T. , Roof, Kevin S. , Robins, H. Ian, Curran, Walter J. , Movsas, Benjamin , Armstrong, Terri S , Wefel, Jeffrey S. , Gilbert, Mark R. , Mehta, Minesh P.

Mayo Clinic

Neurosurgery | February 15, 2018 | Volume: 84 | Issue: 1 | Pages: 66-76

10.1093/neuros/nyy003 | PMID 29618054 Get It

Abstract BACKGROUND The influence of subtotal resection (STR) on neurocognitive function (NCF), quality of life, and symptom burden in glioblastoma is unknown. If bevacizumab preferentially benefits patients with STR is unknown. OBJECTIVE To examine these uncertainties. METHODS NCF and patient reported outcomes (PRO) were prospectively collected in NRG Oncology RTOG 0525 and 0825. Changes in NCF and PRO measures from baseline to prespecified times were examined by Wilcoxon test, and mixed effects longitudinal modeling, to assess differences between patients who received STR vs gross-total resection. Changes were also compared among STR patients on 0825 receiving placebo vs bevacizumab to assess for a preferential therapeutic effect. Overall survival between STR and gross-total resection patients was compared using the Kaplan–Meier method. RESULTS A total of 427 patients were eligible with STR present in 37%. At baseline, patients with STR had worse NCF, worse MD Anderson Symptom Inventory Brain Tumor Neurological Factor ratings ( P = .004), and European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire ( P = .002). Longitudinal multivariate analysis associated STR with worse NCF (Hopkins Verbal Learning Test–Revised Delayed Recognition [ P = .048], Trail Making Test Part A [ P = .035], and Controlled Oral Word Association [ P = .049]). One hundred eighty-three STR patients from 0825 were analyzed (89 bevacizumab, 94 placebo); bevacizumab failed to demonstrate improvement in select NCF or PRO measures. CONCLUSION STR patients had worse NCF and PROs before therapy. During adjuvant therapy, STR patients had worse objective NCF, despite accounting for tumor location. STR did not result in a detriment to OS. The addition of bevacizumab did not preferentially improve PRO or NCF outcomes in STR patients.
Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database
Blumenthal, Deborah T. , Won, Minhee , Brown, Paul D. , Bokstein, Felix , Brachman, David, Werner‐Wasik, Maria, Hunter, G.K., Valeinis, Egils , Hopkins, Kirsten, Souhami, Luís, Howard, Steven , Lieberman, Frank S. , Shrieve, Dennis C. , Wendland, Merideth M, Robinson, Clifford G. , Corn, Benjamin W. , Robinson, Clifford , Mehta, Minesh P. , Gilbert, Mark R. , Zhang, Peixin

Mayo Clinic

Neuro-Oncology | February 13, 2018 | Volume: 20 | Issue: 7 | Pages: 966-974

10.1093/neuonc/noy017 | PMID 29462493 Get It

Are Clinical Certainty Ratings Helpful in the Diagnosis of Parkinson's Disease?
Gupta, Harsh , Mehta, Shyamal H. , Hentz, Joseph G. , Shill, Holly A. , Driver‐Dunckley, Erika, Belden, Christine M. , Beach, Thomas G. , Sue, Lucia I., Davis, Kathryn, Gupta, Harsh V, Driver-Dunckley, Erika, Adler, C H , Zhang, Nan , Driver‐Dunckley, Erika , Sabbagh, Marwan Noel , Dugger, Brittany N. , Serrano, Geidy E. , Adler, Charles H.

Mayo Clinic

Movement Disorders Clinical Practice | January 15, 2018 | Volume: 5 | Issue: 2 | Pages: 165-170

10.1002/mdc3.12589 | PMID 30363433 Get It

AbstractBackgroundClinical diagnostic criteria for PD rely on rest tremor, bradykinesia, and rigidity. These features are non‐specific and neuropathological confirmation remains the gold standard for diagnosis. This study presents data on clinical certainty ratings in autopsy‐proven PD.MethodsSubjects were assessed annually by a movement disorders specialist and assigned to a clinical certainty group for PD based on multiple clinical features before autopsy. The three groups considered for analysis are as follows: Group I 0–49% certainty, Group II 50‐89% certainty, and Group III 90–100% certainty. All subjects were autopsied and had a standardized neuropathological assessment.Results275 subjects were assigned a PD certainty at their last visit before death. Group I had 80 subjects, Group II 56 subjects, and Group III 139 subjects. The clinical features recorded in Group I, II, and III, were as follows: rest tremor, bradykinesia, rigidity, postural instability, asymmetric onset, persistent asymmetry, current response to dopaminergic treatment, motor fluctuations, and dyskinesia. Rigidity, postural instability, asymmetric onset, current response to dopaminergic treatment, motor fluctuation, and dyskinesia were more likely to be present in the group which was rated with higher certainty. The final diagnosis of PD was confirmed by neuropathological assessment in 85% of the patients in Group III as compared to 30% in Group II and 5% in Group I.ConclusionsHigh certainty (90–100%) had strong positive predictive value (85%) for autopsy‐proven PD as compared to either lower certainty groups (0–49% and 50–89%) which had lower predictive value (5% and 30% respectively).